Monday, November 19, 2007

poll: migraine med formula preferences


New to Somebody Heal Me? Subscribe to the Somebody Heal Me feed:
Subscribe in a reader or subscribe by e-mail. Follow me on Twitter @somebodyhealme.

Research published in Headache: The Journal of Head and Face Pain shows that although most patients say they prefer taking the triptan Zomig in pill form, after being exposed to the orally disintegrating tablet and nasal spray forms, almost half of patients express a preference for the orally disintegrating tablet form. It seems that most people have not been exposed to the other options. But when they are, they appreciate having access to those alternatives.

Patient Preference for Triptan Formulations
At baseline, most patients expressed a preference for conventional tablets. After 4 months, 46.9% of patients preferred zolmitriptan ODT, 43.8% zolmitriptan nasal spray, and 6.3% the conventional tablet. The most common reasons given for preferring conventional tablets were personal reasons: for zolmitriptan ODT, convenience and, to a lesser extent, speed of onset: for zolmitriptan nasal spray, speed of onset, and overall efficacy. MIDAS scores decreased significantly following treatment with zolmitriptan. Zolmitriptan was well tolerated.
If you use a triptan that has other formulations than the standard pill available I encourage you to try them. Alternative delivery methods can be preferable because they allow you to get faster relief and avoid complications from nausea and vomiting.

I prefer to use Zomig Nasal Spray and Imitrex StatDose subcutaneous injections. These are the two that work the best for me, and it is nice to know I don't have to worry about keeping a pill down to get relief. They work much faster than pills do, too.

If you have a delivery method preference, share why and which triptans you use in the comments.


Technorati Tags: , , , , , , ,

Subscribe to the Somebody Heal Me feed: Subscribe in a reader or subscribe by e-mail.

Photo Sharing and Video Hosting at Photobucket Content by Diana E. Lee.